Remzistotug

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Squamous Cell CarcinomaNeoplasmsNeoplasms, Head and Neck

279 competitors in Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 3

202

Taxol

Teva

Phase 3

113

Tecentriq

Roche

Phase 3

64

Paraplatin

AAvyxa

Phase 3

195

Libtayo

Regeneron

Phase 3

56

Yervoy

Bristol-Myers Squibb

Phase 3

47

Vectibix

Amgen

Phase 3

38

Beyfortus

BeiGene

Phase 3

29

Gilotrif

Boehringer Ingelheim

Phase 3

1010

Tarceva

DDutch Society of Physicians for Pulmonology and Tuberculosis

Phase 3

9Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Neoplasms1 trial

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

Active, not recruiting·GSK·Phase 1·NCT05277051·152 enrolled

Neoplasms, Head and Neck1 trial

A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting·GSK·Phase 2·NCT06062420·316 enrolled

Details

Drug Info

Related News